Partager cette page
Résultats des concours de financement de 2018-19 du RCS : essais cliniques
| Chercheur principal | Cochercheurs | Titre du projet | Fonds du RCS |
|---|---|---|---|
| Jean Roy – Hôpital Maisonneuve- Rosemont (HMR) | Guy Sauvageau (UMontréal), Jean-Sebastien Delisle (HMR), Richard Leblanc (HMR), Sandra Cohen (HMR), Silvy Lachance (HMR), Imran Ahmad (HMR), Émilie Lemieux-Blanchard (CRCHUM), Michael Sebag (MUHC), Sebastien Lemieux (UMontréal), Gabriel Tremblay (Geneconomic) | Allogeneic stem cell transplant using UM171 expanded cord bloods for patients with high-risk multiple myeloma | 500 000 $ |
| James Shapiro – U of A | Peter Senior (U of A), Peter Light (U of A), Gregory Korbutt (U of A), Eugene Brandon (Viacyte Inc.), Howard Foyt (Viacyte Inc.), Sylvain Bedard (CEPPP), Bart Roep (U Leiden), Joanna Preston (TEC Edmonton), Chris McCabe (U of A) | Pancreatic Progenitor Cell Therapy: Solving Supply and Survival Issues of Islet Cell Transplantation for T1DM | 500 000 $ |
| Duncan Stewart – OHRI | David Courtman (GMP Facility OHRI), Michael Kutryk (SMH), Chris Glover (UOHI), Hung-Ly Quoc (MHI), Alexander Dick (UOHI), Michel Lemay (UOHI), Kim Connelly (SMH), Howard Leong Poi (SMH), Josep Rodes-Cabau (U Laval), Dominique Joyal (JGH), Vincent Laroche (U Laval) | Enhanced Angiogenic Cell Therapy for Acute Myocardial Infarction (ENACT-AMI) | 500 000 $ |
Sommaire pour le programme des essais cliniques
| Demandes reçues | Demandes dont l’acceptation est recommandée | Pourcentage d’acceptation des demandes | Investissement total |
|---|---|---|---|
| 4 | 3 | 75% | 1,5 M$ |
Résultats des concours de financement de 2018-19 du RCS : programme d’équipes de recherche sur les maladies
| Chercheur principal | Cochercheurs | Titre du projet | Fonds du RCS |
|---|---|---|---|
| Gilbert Bernier – Hôpital Maisonneuve- Rosemont (HMR) | May Griffith (UMontréal), Jean-Francois Bouchard (UMontréal), Flavio Rezende (HMR), Cynthia Qian (UMontréal), Mario Filion (INRS) | Macula transplantation for the treatment of retinal degenerative diseases | 200 000 $ |
| Joanna Matsubara – UBC | Marinko Sarunic (SFU), Orson Moritz (UBC), Sean Lumb (UBC), Christopher Laver (UBC) | Treating advanced retinal degeneration – rebuilding multiple co-dependent retinal layers with stem cells | 100 000 $ |
| Lauralyn McIntyre – OHRI | Shirley Mei (OHRI), Duncan Stewart (OHRI), Dean Fergusson (OHRI), John Marshall (SMH), Keith Walley (UBC), Claudia dos Santos (SMH), Brent Winston (U of C), Shane English (OHRI), Alexis Turgeon (U Laval), Geeta Mehta (U of T), Robert Green (DU), Alison Fox-Robichaud (Hamilton Health Sciences Corporation), Margaret Herridge (UHN), John Granton (U of T), Paul Hebert (CRCHUM), Kednapa Thavorn (OHRI), Timothy Ramsay (OHRI), David Courtman (GMP Facility OHRI), Dana Devine (CBS), Sowmya Viswanathan (UHN) | Cellular Immunotherapy for Septic Shock (CISS2): A Phase II Multicentre Clinical Trial | 200 000 $ |
| Freda Miller – Hospital for Sick Children (HSC) | Donald Mabbott (HSC), David Kaplan (HSC), Cindi Morshead (U of T), Jing Wang (OHRI), Ann Yeh (HSC), Douglas Munoz (Queens U), Paul Frankland (HSC), Wolfram Tetzlaff (UBC) | Pharmacological recruitment of endogenous neural precursors to promote pediatric white matter repair | 200 000 $ |
| Massimiliano Paganelli – CHU Sainte-Justine, UMontréal | Elie Haddad (UMontréal), Christian Beausejour (UMontréal) | Safety and efficacy of stem cell-derived encapsulated liver tissue to treat liver failure without immunosuppression | 100 000 $ |
| James Shapiro – U of A | Gregory Korbutt (U of A), ViaCyte Inc., Joanna Preston (TEC Edmonton), Peter Senior (U of A), Bruce Verchere (UBC) | Development of a novel stem cell-derived transplant modality for type 1 diabetes | 100 000 $ |
| Bruce Verchere – UBC | Francis Lynn (UBC), Megan Levings (UBC), Tim Kieffer (UBC), Dina Panagiotopoulos (UBC), Brad Hoffman (UBC), Garth Warnock (UBC), Gregory Korbutt (UofA) | Genetic manipulation of hES-derived insulin-producing cells to improve graft outcomes | 200 000 $ |
Sommaire pour le programme des équipes de recherche sur les maladies
| Demandes reçues | Demandes dont l’acceptation est recommandée | Pourcentage d’acceptation des demandes | Investissement total |
|---|---|---|---|
| 11 | 7 | 64% | 1,1 M$ |
Résultats des concours de financement de 2018-19 du RCS : programme de recherches d’impact
| Chercheur | Axe de recherche | Titre du projet | Fonds du RCS |
|---|---|---|---|
| Florian Bentzinger – USherbrooke (Principal Investigator) Eric Marsault (USherbrooke), Mannix Auger-Messier (USherbrooke), Nicolas Dumont (CHU-Sainte-Justine, UMontréal), Frederic Balg (USherbrooke) | Transfert des découvertes | Apelinergic Compounds for the treatment of muscular dystrophy | 99 000 $ |
| Mick Bhatia – McMaster (Principal Investigator) Rima Al-Awar (OICR) | Transfert des découvertes | Identification of kinases and their target substrates in early human PSC specification | 100 000 $ |
| Timothy Caulfield – U of A (Principal Investigator) Amy Zarzeczny (UofR), Barbara von Tigerstrom (UofA), Tania Bubela (SFU), Yann Joly (McGill), Zubin Master (Mayo Clinic), Jeremy Snyder (SFU), Ubaka Ogbogu (UofA) | Politique publique | The Next Step: Specific Strategies for Addressing the Marketing of Unproven Stem Cell Therapies | 40 000 $ |
| Nicolas Dumont – CHU Sainte-Justine, UdeM (Principal Investigator) Sylvie Girard (UdeM), Cam-Tu Nguyen (UdeM), Phillipe Campeau (UdeM), Christian Beauséjour (UdeM) | Transfert des découvertes | Targeting muscle stem cells to mitigate Duchenne muscular dystrophy | 100 000 $ |
| John Hassell – McMaster (Principal Investigator) Rima Al-awar (OICR) | Transfert des découvertes | HTR5A as a target for anticancer stem cell drug discovery | 99 500 $ |
| Timothy Kieffer – UBC (Principal Investigator) Ali Rezania (Viacyte Inc.) | Application et accélérateur cliniques | Assessment of Cell Maturation and Function in Subcutaneous Macroencapsulation Devices in Rodents | 100 000 $ |
| Bartha Knoppers – McGill (Principal Investigator) Rosario Isai (OHRI), Tim Caulfield (UofA), Amy Zarzeczny (UofR), Tania Bubela (SFU), Ubaka Ogbogu (UofA), Vardit Ravitsky (UdeM) | Politique publique | Reforming Canadian Stem Cell Policy: Moving Beyond the Assisted Human Reproduction Act (AHRA) | 39 736 $ |
| Zachary Laksman – UBC (Principal Investigator) Glen Tibbits (SFU) | Application et accélérateur cliniques | Using stem cells to test new drugs for atrial fibrillation | 100 000 $ |
| Lauralyn McIntyre – OHRI (Principal Investigator) Shirley Mei (OHRI), Duncan Stewart (OHRI), Dean Fergusson (OHRI), John Marshall (SMH), Keith Walley (UBC), Claudia dos Santos (SMH), Brent Winston (U of C), Shane English (OHRI), Alexis Turgeon (U Laval), Geeta Mehta (U of T), Robert Green (DU), Alison Fox-Robichaud (McMaster), Margaret Herridge (U of T), John Granton (U of T), Paul Hebert (CRCHUM), Kednapa Thavorn (OHRI), Timothy Ramsay (OHRI), Sowmya Viswanathan (UHN) | Application et accélérateur cliniques | Cellular Immunotherapy for Septic Shock (CISS): A Phase II Multicentre Clinical Trial | 100 000 $ |
| Derrick Rancourt – UC (Principal Investigator) | Commercialisation | Enhancing the Efficiency of Genome Engineering in Human Pluripotent Stem Cells | 100 000 $ |
| Bernard Thébaud – OHRI (Principal Investigator) Mervin Yoder (Hospital for Children, Indianapolis), Dylan Burger (U of O) | Application et accélérateur cliniques | Endothelial Progenitor Cell-derived Therapies for Neonatal Pulmonary Hypertension | 99 905 $ |
| Glen Tibbits – SFU (Principal Investigator) Thomas Claydon (SFU), Zachary Laksman (UBC), Shubhayan Sanatani (UBC) | Application et accélérateur cliniques | Developing an hiPSC-CM based protocol to investigate SIDS-implicated sudden cardiac arrest in infants | 99 500 $ |
| Eve Tsai – OHRI (Principal Investigator) Xudong Cao (U of O), Ruth Slack (U of O) | Application et accélérateur cliniques | Translating an animal endogenous stem/progenitor cell repair strategy for stroke to humans | 100 000 $ |
| Peter Zandstra – UBC (Principal Investigator) Fiona Watt (King’s College, London, UK), Davide Danovi (King’s College, London, UK) | Commercialisation | A robust, quantitative, and high-throughput assay to rapidly characterize human induced pluripotent stem cells | 100 000 $ |
Sommaire du programme de recherche d’impact
| Demandes reçues | Demandes dont l’acceptation recommandée | Pourcentage d’acceptation des demandes | Investissement total |
|---|---|---|---|
| 46 | 14 | 30% | 1,4 M$ |
* Les titres des projets sont affichés selon la langue de soumission